Cipher Pharmaceuticals Inc banner

Cipher Pharmaceuticals Inc
TSX:CPH

Watchlist Manager
Cipher Pharmaceuticals Inc Logo
Cipher Pharmaceuticals Inc
TSX:CPH
Watchlist
Price: 17.71 CAD -2.15%
Market Cap: CA$447.7m

Cipher Pharmaceuticals Inc
Cash Taxes Paid

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Cipher Pharmaceuticals Inc
Cash Taxes Paid Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Taxes Paid CAGR 3Y CAGR 5Y CAGR 10Y
Cipher Pharmaceuticals Inc
TSX:CPH
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bausch Health Companies Inc
TSX:BHC
Cash Taxes Paid
$163m
CAGR 3-Years
-15%
CAGR 5-Years
0%
CAGR 10-Years
6%
Canopy Growth Corp
TSX:WEED
Cash Taxes Paid
CA$481k
CAGR 3-Years
-41%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Cronos Group Inc
TSX:CRON
Cash Taxes Paid
$104k
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Cash Taxes Paid
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Cash Taxes Paid
CA$2.9m
CAGR 3-Years
-20%
CAGR 5-Years
-15%
CAGR 10-Years
4%
No Stocks Found

Cipher Pharmaceuticals Inc
Glance View

Market Cap
447.7m CAD
Industry
Pharmaceuticals

Cipher Pharmaceuticals, Inc. engages as a specialty pharmaceutical company, which have diversified portfolio of commercial and early to late-stage products. The company is headquartered in Oakville, Ontario. The company went IPO on 2004-02-25. The firm acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products directly in Canada and indirectly through partners in the United States, Canada and South America. Its Dermatology products include Actikerall, Epuris, Ozanex, and Vaniqa. Its Hospital Acute Care products are Aggrastat and Brinavess. The Company’s Out-Licensed Products include Absorica, ConZip, Durela, and Lipofen. The company is focused on three strategy that includes acquisitions, in-licensing, and selective investments in drug development to assemble a portfolio of prescription products that serve unmet medical needs. The firm's subsidiaries include Cipher US Holdings Inc., Cipher US Holdco LLC and Cipher Pharmaceuticals US LLC.

CPH Intrinsic Value
12.94 CAD
Overvaluation 27%
Intrinsic Value
Price CA$17.71

See Also

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett